Moderna, Inc. - Common Stock (MRNA)

Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices.

The U.S. Centers for Disease Control and Prevention reversed course Wednesday, reinstating approximately 450 employees previously laid off under the Trump administration's federal workforce reduction initiative.

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.

The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule.

A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.

Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."

A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.

A number of stocks jumped in the afternoon session after the major indices rebounded, as the Bureau of Labor Statistics report revealed a resilient labor market with non-farm payrolls rising by 139,000 in May 2025, significantly above the consensus forecast of 125,000. 

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Thursday. Discover the gap up and gap down stocks in the S&P500 index.

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Monday after the company announced its new COVID-19 vaccine secured clearance from the U.S. Food and Drug Administration (FDA) for seniors and at-risk individuals.

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

Investor sentiment on Moderna turned bearish over the weekend despite FDA approval of its new COVID-19 vaccine, mNEXSPIKE, which showed higher efficacy and a favorable safety profile.

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends.

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.